LLY - Eli Lilly and Company Pick

Serene mountain lake reflecting sunlit peaks and forest.

Research brief

Jul 15, 2026 Morning

01:00 PM UTC

Eli Lilly and Company LLY low

LLY

Conf. Low

Pick Pr. $1144.54

Stop Pr. $1073.01

Curr. Pr. $1154.00

Change +0.83%

Rem. Days 35

Summary

Recommendation: Buy one standard portfolio slot of LLY at approximately $1,138.96, the 10:34 ET quote on July 15, with Low confidence. The stock had a feasible structural stop and the highest refreshed modeled net return among the passing finalists. finance.yahoo
The fresh edge is the FDA's July 14 traditional approval of Retevmo for eligible RET-fusion-positive solid-tumor patients. It removes regulatory uncertainty for the indication, but earlier accelerated approvals mean the event is de-risking rather than a new franchise launch. fda.gov
Analyst scenario estimate: a 35% target case, 25% stop case, and 40% time-exit case produce a +1.65% expected net return after 0.10% estimated friction. These probabilities and friction are assumptions, not observed facts or guarantees.
The path is imperfect: first resistance at $1,166.58 is only 2.43% above entry and about 0.42R away, while the five-week terminal target remains $1,230.00. finance.yahoo
Risk control is decisive: exit on the first regular-session breach of $1,073.00, protect breakeven or better after an early test of first resistance, and close no later than August 4 to avoid carrying the new position through August 5 earnings. finance.yahooinvestor.lill

Why Now

The catalyst is completed and objective. On July 14, the FDA converted Retevmo's indication for eligible RET-fusion-positive solid tumors to traditional approval. Because adults and pediatric patients already had accelerated approvals, the event strengthens regulatory durability but does not by itself establish a large new revenue pool. fda.gov

The entry edge comes from the combination of that de-risking event, strong operating capacity, and manageable downside geometry. Lilly reported Q1 revenue of $19.8 billion, net income of $7.4 billion, and raised 2026 guidance to $82–85 billion of revenue and $35.50–$37.00 of non-GAAP EPS. investor.lill At the refreshed quote, the stock had not triggered the post-catalyst over-extension gate: it was below session VWAP and the completed approval was followed by a decline, not a 10% or 2.5-ATR upside repricing. finance.yahoo

The edge is narrow. DASH, the best remaining viable candidate, had a modeled +1.59% net return versus LLY's +1.65%, stronger intraday tape, and a slightly better 0.49R path to first resistance. LLY prevailed because DASH's Shopify integration disclosed no pricing, revenue-share, merchant-count, or revenue-timing economics, while DASH's beta was 1.78 versus LLY's 0.51. finance.yahooir.doordashfinance.yahoo The roughly 0.06-percentage-point modeled advantage is too small to justify more than Low confidence.

Business And Market Context

For this trade, Lilly's relevant business context is a large earnings base supporting a specialized-oncology regulatory catalyst. Retevmo targets a biomarker-defined population, so the approval's importance is clearer as portfolio de-risking than as evidence of an immediate company-wide growth step-change. fda.gov The broader operating platform is the stabilizer: current revenue, profit, and raised annual guidance reduce reliance on this single approval to support the risk plan. investor.lill

The market backdrop allows selective long exposure but does not provide a broad-beta tailwind. Around 10:35–10:36 ET, SPY was above its prior close, while QQQ was below its prior close and session VWAP; the evidence characterized this as selective risk-on rather than a crash or bear regime. finance.yahoofinance.yahoo That mixed tape favors Lilly's lower beta and completed catalyst, but it also argues against loosening the stop or chasing above the quoted entry.

Portfolio-wise, LLY does not duplicate the existing DAL, DTE, or KTOS positions. This is a portfolio-construction observation based on the supplied holdings, not an external factual claim.

Factor Stack

Factor	Assessment	Evidence and interpretation
Catalyst/news	Positive, limited magnitude	The July 14 FDA action is fresh, completed, and objective, but it converts an existing accelerated approval rather than opening a wholly new franchise. fda.gov
Growth and profitability	Positive	Q1 revenue was $19.8 billion, net income was $7.4 billion, and 2026 revenue and non-GAAP EPS guidance were raised. investor.lill
Valuation	Unconfirmed / risk	The supplied evidence did not include a current earnings multiple, peer comparison, or decision-grade intrinsic valuation. Valuation therefore does not support the recommendation; the $1,230 target is a scenario and price-path assumption inside a recent trading range, not a fair-value estimate. finance.yahoo
Momentum and relative strength	Mixed	The stock had outperformed SPY by 3.05 percentage points over 20 sessions, but the refreshed quote was below session VWAP and the SMA20 resistance at $1,166.58. finance.yahoo This is relative resilience without clean short-term confirmation.
Sentiment/social confirmation	Unconfirmed	Evidence limitation: the supplied research found no decision-grade, Retevmo-specific community confirmation. Broader discussion centered on Lilly's GLP-1 pipeline and valuation, so sentiment was not used to raise the target probability.
EPS revisions	Partially positive	Lilly raised its own 2026 revenue and non-GAAP EPS guidance, which supports operating direction. investor.lill Evidence limitation: no current independent analyst-consensus revision series was supplied, so company guidance should not be presented as verified upward consensus revisions.

Investment Thesis

The thesis is that a completed regulatory de-risking event, strong operating capacity, lower beta, and a feasible structural stop create the best positive expected-return setup in the supplied finalist slate. The stock does not need a new high to satisfy the terminal case: the $1,230 target is about 7.99% above the $1,138.96 entry and sits within the cited recent $1,238–$1,249 range. finance.yahoo

The first obstacle is deliberately separate from the target. The $1,166.58 SMA20 resistance is about 2.43% above entry and only 0.42R from it; reaching that level would show that the post-approval decline is repairing, but it is not the terminal objective. finance.yahoo

Analyst scenario assumptions:

Outcome	Probability	Return assumption	Trade implication
Target at $1,230	35%	+7.993%	Take profit if reached before the mandatory exit.
Stop at $1,073	25%	-5.791%	Exit on the first regular-session breach.
Time exit	40%	+1.000%	Close by August 4 if neither price level is reached.

After the 0.10% estimated round-trip friction assumption, the modeled return is 35% × 7.993% + 25% × -5.791% + 40% × 1.000% - 0.100% = +1.650%, or about +0.285R. The probabilities are analyst judgments and the output is an estimate, not a forecast guarantee. The scenario inputs and geometry were validated against the refreshed quote. finance.yahoo

Risks And Thesis Breakers

Weak catalyst transmission: Retevmo's traditional approval mainly de-risks an already approved indication; failure of the stock to respond constructively is evidence that the event may be too small to reprice Lilly over this holding window. fda.govfinance.yahoo
Entry and resistance risk: the quote was below session VWAP, and first resistance is only 0.42R away. A rejection at $1,166.58 is not automatically fatal, but persistent failure to reclaim it reduces the probability of reaching $1,230. finance.yahoo
Hard price invalidation: a first regular-session breach of $1,073 breaks the structural setup because that stop sits beneath the June $1,079.22 swing low and about 1.58 ATR below entry. finance.yahoo
Earnings gap risk: Lilly reports on August 5. An ordinary stop may not protect against an overnight earnings gap, so the recommendation explicitly forbids carrying this new position past the August 4 close without a fresh, separate underwriting. investor.lill
Valuation and estimate-evidence limitation: no current peer-relative multiple or independent EPS-revision series was supplied. If the market derates high-multiple healthcare shares, the operating strength cited here may not prevent a price decline.
Market risk: the mixed SPY/QQQ tape is selective rather than broadly supportive. A deterioration from that regime could pressure even a lower-beta candidate. finance.yahoofinance.yahoo
Execution risk: $1,138.96 is a time-stamped intraday quote, not a guaranteed fill. A materially higher entry worsens target upside and stop distance; this report does not authorize silently widening the $1,073 stop. finance.yahoo

Investment Recommendation

Buy one standard portfolio slot of LLY now near the supplied $1,138.96 quote, with Low confidence. Do not wait for a lower pullback or convert $1,166.58 into a mandatory entry trigger; the authoritative decision is an immediate buy, and first resistance remains a path diagnostic rather than the five-week target. finance.yahoo

Use the following explicit risk plan:

Set the structural stop at $1,073.00, equivalent to 5.79% below the supplied entry. Exit on the first regular-session breach; do not widen the stop. finance.yahoo
Keep $1,166.58 as the first-resistance checkpoint. If reached early, raise protection to breakeven or better so a successful first leg cannot become a full-stop loss. finance.yahoo
Keep the decider's terminal target at $1,230.00. Take profit if reached before the event deadline; do not replace it with the nearer resistance level. finance.yahoo
Close the position by the August 4 regular-session close if neither stop nor target has executed. Do not carry the trade unhedged into August 5 earnings. investor.lill

This is a tightly managed pre-earnings catalyst trade, not an unattended 35-calendar-day hold. Its modeled edge over DASH is only about 0.06 percentage point, and the absence of decision-grade valuation, independent revision, and catalyst-specific sentiment evidence makes strict execution—not conviction—the core of the recommendation.